Immuneering raises $25M in private placement at $3.95/unit, warrants at $5.50

Immuneering Corp

$25M gross proceeds from 6.33M shares (or pre-funded warrants) and 2.85M warrants at $5.50.
Combined purchase price of $3.95 per unit, representing a ~15% premium over Aug. 20 close.
Proceeds to support clinical development of atebimetinib in first-line pancreatic cancer.
Closing expected on or about August 26, 2025; registration rights agreement filed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.